STAAR Surgical Celebrates Three Million Lens Milestone at ASCRS Meeting, Unveils New EVO ICL Data and Latest Innovation for 2024
- Scientific content at ASCRS related to EVO ICL™ doubles with 44 posters and presentations
-
STAAR is leading a comprehensive clinical education program including a lunch symposium, multiple in-booth and offsite events, as well as online through the launch of
STAAR University -
EVO ICL advocate,
Will Levis , Tennessee Titans Quarterback, sharing his EVO ICL experience in the STAAR booth Saturday,11:30 a.m. –1:00 p.m. ET - Previewing Stella™, STAAR’s new ordering and planning platform, launching Spring/Summer ‘24
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240402599401/en/
(Graphic: Business Wire)
“EVO ICL is the next logical step in refractive innovation. While adoption of any new technology takes time, EVO ICL’s adoption rate has been steadily rising since launch – achieving market leadership in key markets – and proving the viability of a global paradigm shift in refractive surgery that both expands the channel, and grows patient adoption within it,” said
Data, Educational Programming and Resources Supporting Clinical Confidence
New clinical data during the scientific session continues to support EVO ICL patient advantages and provide insights to guide successful implementation in practice. On
STAAR is also supporting clinical confidence through the following educational programs and events:
-
Lunch Symposium: Modernizing Refractive Surgery – Expanding Options for Myopic Patients with EVO ICL,
Friday, April 5 ,11:30 a.m. –1:00 p.m. Room I53ABC -
Navigating Early Experience with EVO ICL, in-booth,
Saturday, April 6 ,10:00 a.m. Booth 527 -
All You Wanted to Know about EVO ICL
but Were Afraid to Ask, a roundtable discussion hosted at two times,
Saturday, April 6 ,12:00 p.m. andSunday, April 7 ,12:00 p.m. Booth 527 -
Discovering EVO ICL in My Early Refractive Training, Booth 527,
Saturday, April 6 ,3:30 p.m.
Registration for in-booth discussions is available at: https://www.surveymonkey.com/r/STAAR-Booth
Registration for roundtable discussions is available at: https://www.surveymonkey.com/r/STAAR-table
Expanding Clinical Affairs Resources, Online and In-Booth at ASCRS
STAAR advances clinical excellence with the launch of
Commercial Confidence through Practice Support
STAAR is leading the way in investment to grow the refractive surgery channel, and supporting surgeons who are ready to grow their business, modernize their practice and maximize their comprehensive refractive offering. Several opportunities to experience STAAR’s practice advantage on display at ASCRS, include:
-
Meet & Greet with Tennessee Titans Quarterback and EVO ICL advocate,
Will Levis , at the STAAR Booth 527, from11:30 a.m. –1:00 p.m. onSaturday, April 6 -
In-booth discussion on
Patient-Centered Communications : Practical Strategies for Discussing EVO ICL,Saturday, April 6 ,1:30 p.m. Booth 527 -
In-booth discussion on Patient Acquisition: Best Practices and Behaviors,
Sunday, April 7 ,10:00 a.m. Booth 527
Innovation Advantage
STAAR will offer an in-booth preview of Stella, STAAR’s latest innovation in ordering, designed to streamline and elevate the EVO ICL ordering and planning process. Appointments for Stella previews are available at https://calendly.com/staar-surgical/stella-training
For more information about EVO Implantable Collamer® Lenses, visit https://evoicl.com. Connect with us on social media at: Facebook, Instagram, and LinkedIn.
About
STAAR, which has been dedicated solely to ophthalmic surgery for over 40 years, designs, develops, manufactures and markets implantable lenses for the eye. These lenses are intended to provide visual freedom for patients, lessening or eliminating the reliance on glasses or contact lenses. All of these lenses are foldable, which permits the surgeon to insert them through a small incision. STAAR’s lens used in refractive surgery is called an Implantable Collamer® Lens or “ICL,” which includes the EVO ICL™ product line. More than 3,000,000 ICLs have been sold to date and STAAR markets these lenses in over 75 countries. To learn more about the ICL go to: EVOICL.com. Headquartered in
Important Safety Information for EVO ICL
The EVO Visian ICL lens is intended to correct/reduce nearsightedness between -3.0 D up to -20.0 D and treat astigmatism from 1.0 D to 4.0
For additional information with potential benefits, risks and complications please visit evoicl.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240402599401/en/
Media
Vice President, Marketing
(626) 303-7902, Ext. 9683
aholmes@staar.com
Investors
Vice President, Investor Relations and Corporate Development
(626) 303-7902, Ext. 3023
bmoore@staar.com
Source: